61 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical
424B3
UBX
Unity Biotechnology Inc
8 Dec 23
Prospectus supplement
4:39pm
requirements, our needs for additional financing, and our ability to obtain additional capital;
the lingering effects of the COVID-19 pandemic and the effects … of any future pandemic on our clinical trials and business;
our ability to maintain compliance with the minimum required closing bid price
8-K
EX-99.1
UBX
Unity Biotechnology Inc
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug
8-K
EX-99.1
vrfdlm v0rbp0
27 Sep 23
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:05am
8-K
EX-99.1
4guq 4gt3rs
8 Aug 23
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
4:04pm
8-K
EX-99.1
jzp3z9stu 7qk9
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.2
i98w2000w p2
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
cv8yhqg9
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
hw84c1vo9bjonapz
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
8-K
EX-99.1
ba3jwdhx
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
8-K
EX-99.2
663jhdwj6cf58jm
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
424B5
1de3x6w38
25 Oct 22
Prospectus supplement for primary offering
9:39pm
424B5
vz58dvo
19 Aug 22
Prospectus supplement for primary offering
8:42am